Refractory Acute Lymphoblastic Leukemia
Oncology
Prevalence
8.0 / 100K
Incidence
1.8 / 100K/yr
4 drugs in development·4 companies·7 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 3(1)
| Drug | Company |
|---|---|
| kte-c19 | Kite Pharma, Inc. (KITE) |
Phase 1(1)
| Drug | Company |
|---|---|
| ADCT-602 | ADC Therapeutics SA (ADCT) |
Compare drugs
Frequently asked questions
How many drugs are in development for Refractory Acute Lymphoblastic Leukemia?
BioSniper tracks 4 drugs in development for Refractory Acute Lymphoblastic Leukemia across 4 companies.
How many clinical trials target Refractory Acute Lymphoblastic Leukemia?
There are 7 clinical trials targeting Refractory Acute Lymphoblastic Leukemia tracked by BioSniper.
What is the prevalence of Refractory Acute Lymphoblastic Leukemia?
The estimated prevalence of Refractory Acute Lymphoblastic Leukemia is approximately 8.0 per 100,000 population.
Deep-dive into Refractory Acute Lymphoblastic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis